相关实验视频

Updated: May 3, 2026

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

一种病毒聚集抑制剂阻断了SARS-CoV-2在呼吸道上皮细胞中的复制

Li Du^1,2, Fred Deiter^2,3, Mohamed S Bouzidi^1,2

¹Vitalant Research Institute, 360 Spear St., San Francisco, CA, 94105, USA.

Communications biology

|April 22, 2024

概括

小分子PAV-104通过阻断病毒粒子组合,有效地抑制SARS-CoV-2的复制. 这种新的治疗候选药物显示出对各种变异的承诺,为COVID-19治疗提供了一种新的策略.

科学领域:

病毒学病毒学
药物发现药物发现药物发现
分子生物学分子生物学

背景情况:

由于SARS-CoV-2不断演变,因此需要具有高耐药性障碍的新疗法.
由于病毒逃避,现有的治疗方法面临挑战,这突显了需要新的药物点的需要.
小分子PAV-104针对病毒组装机械,对SARS-CoV-2具有特异性.

研究的目的:

调查PAV-104在抑制人类呼吸道上皮细胞 (AEC) 中SARS-CoV-2复制的疗效.
阐明PAV-104对SARS-CoV-2的作用机制.
评估PAV-104作为COVID-19治疗候选药物的潜力.

主要方法:

测试了PAV-104对其抑制SARS-CoV-2感染的能力,在人类永生和初级AEC (空气液体接口模型) 中进行了测试.
评估了病毒的进入,mRNA转录,蛋白质合成和粒子组装.
进行了转录基因分析,以了解PAV-104对宿主细胞反应的影响.

主要成果:

在AEC中,PAV-104抑制了多种SARS-CoV-2变异的99%以上的感染.
该药物通过干扰核体 (N) 蛋白质寡合化和粒子组装来阻止SARS-CoV-2的产生,而不会影响病毒的进入或早期复制步骤.
PAV-104逆转了SARS-CoV-2诱导的I型干扰素反应和核蛋白信号通路.

结论:

在相关的人类细胞模型中,PAV-104显示出对SARS-CoV-2的强有力的抗病毒活性.
它独特的抑制病毒聚集的机制提供了独特的治疗方法.
PAV-104代表了COVID-19治疗的有希望的候选人,与目前的疗法不同.

更多相关视频

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Generation and Assembly of Virus-Specific Nucleocapsids of the Respiratory Syncytial Virus

Published on: July 27, 2021

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions

Published on: September 22, 2023

相关概念视频

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...